Clinical Observation Of Chemotherapy Regimens Containing Decitabine To Treat Myelodysplastic Syndrome And Acute Myeloid Leukemia

Objective:To investigate the clinical effect and safety of decitabine regimen in the treatment of myelodysplastic syndrome(MDS)and acute myeloid leukemia(AML).Method:Clinical data of 84 patients with MDS or AML treated by chemotherapy regimens containing decitabine from January 2016 to June2017 were analyzed retrospectively.Among 84 patients,there were 21 cases of MDS and 63 cases of AML,and the clinical outcome,adverse reactions were recorded.Results:Among 84 patients with MDS or AML,complete remission(CR)was59 cases(70.23%),partial remission rate(PR)was 11 cases(13.1%).The total effective rate was 83.33%(70/84).The mortality rate due to adverse reaction was 4.76%(4/84).Conclusion:Decitabine alone or combined regimens can effectively treat MDS and AML in some extent and delay the progress of diseases.The main adversereactions as bone marrow suppression and infection,blood transfusion,anti-infection supportive treatment were required.